Posted by Gary Schwitzer in Health care journalism
I met yesterday with the World Press Institute’s 2008 International Fellows. They came from Argentina, Brazil, Bosnia & Herzegovina, China, Hungary, India, Lithuania, South Africa and Spain.
We reviewed recent examples of U.S. health journalism.
Several of the Fellows expressed amazement at what they saw. Among the comments:
• They couldn’t believe that stories promoted drugs without better discussion of evidence.
• They couldn’t believe that drug company spokesmen were interviewed in stories.
• They couldn’t believe that someone in news organizations didn’t say “NO” to some of the stories they saw here.
Welcome to our world.
Comments are closed.
Treatment for advanced ovarian tumors may lengthen survival, but questions still remain, despite the story’s emphasis on “promising” and “new hope.”
As with the HealthDay story on this research that we reviewed, readers of this story get a good dose of caveats and cautions along with the suggestions that electrical brain stimulation might someday “have implications” for treatment of Alzheimer’s disease.
The readers of this story and the other one we reviewed by Reuters are likely to understand that electrical brain stimulation could have some memory effects, but it’s a long way from becoming a treatment for Alzheimer’s disease.
We will not display your name or e-mail address on the site, nor will we share youre-mail address with any third parties.
For site updates and news from Gary, find us on Twitter:
HealthNewsReview: @HealthNewsRevu
Gary Schwitzer: @garyschwitzer
Copyright © 2012 Health News Review
